Drug interactions
Regorafenib + Vemurafenib
Severity: Minor
Regorafenib and Vemurafenib: minor interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
Regorafenib may inhibit BCRP, and vemurafenib is a substrate of this transporter. Vemurafenib exposure could increase, with more skin, joint, liver and QT-related adverse effects, but the magnitude is unknown.
What this interaction means in plain words
Regorafenib and Vemurafenib have a small, usually unimportant interaction. Most people can take both; the pharmacist may still mention it so that any unexpected effect is recognised.
Regorafenib belongs to Oncology; Vemurafenib belongs to Oncology.
Why it happens
Predicted BCRP (ABCG2) inhibition by regorafenib raising vemurafenib exposure.
What to do
Monitor liver enzymes, ECG/QTc and dermatologic toxicity; reduce vemurafenib dose if toxicity emerges.
What to ask your pharmacist
- Is there anything I should notice while taking both?
- Do I need to tell my doctor at the next visit?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Regorafenib and Vemurafenib, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 14 days on the web. No card needed.
Other interactions of Regorafenib
Other interactions of Vemurafenib
Frequently asked questions
Can I take Regorafenib with Vemurafenib?
MediHelp rates the interaction as minor. Regorafenib and Vemurafenib have a small, usually unimportant interaction. Most people can take both; the pharmacist may still mention it so that any unexpected effect is recognised. Regorafenib may inhibit BCRP, and vemurafenib is a substrate of this transporter. Vemurafenib exposure could increase, with more skin, joint, liver and QT-related adverse effects, but the magnitude is unknown.
How serious is the interaction between Regorafenib and Vemurafenib?
MediHelp rates it minor, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Monitor liver enzymes, ECG/QTc and dermatologic toxicity; reduce vemurafenib dose if toxicity emerges.
What other medicines interact with Regorafenib?
MediHelp also lists interactions of Regorafenib with, for example, Apalutamide, Atazanavir, Carbamazepine. The full list is on the Regorafenib page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
